CONGRESS FOR VOTERS

RepublicanBill · H.R. 679· House(119-HR-679)

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Rep. Harshbarger
Age: 66 years
Tennessee
Introduced
1/23/2025
Last activity
1/23/2025 — Referred to the House Committee on Energy and Commerce.
Sponsored by
Diana Harshbarger
Cosponsors
Republican - 18Democrat - 0
Health
  1. Introduced
  2. In Committee

What this bill would do

This bill seeks to nullify the changes made by the Food and Drug Administration in January 2023 regarding the risk evaluation and mitigation strategy for mifepristone. It specifically targets the modifications made to the strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act. Additionally, the bill prevents the Secretary of Health and Human Services from implementing any provisions that are substantially similar to those nullified modifications.

Yes

  • Does this give the federal government more power?+3

    The bill uses congressional authority to nullify specific regulatory actions taken by the FDA and HHS.

The opposite· 3 of 5

  • Would women be better off under this?-7

    The bill restricts reproductive options by nullifying the FDA's expanded access to mifepristone.

  • Does this make abortion easier to get?-7

    The bill nullifies FDA modifications to mifepristone distribution, which likely restricts access to the medication by reverting to more restrictive oversight.

  • Does this narrow the gap between how men and women are treated?-5

    By restricting the distribution of mifepristone, the bill potentially reduces women's autonomy over reproductive healthcare.